BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1297 related articles for article (PubMed ID: 12709465)

  • 41. Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial.
    Yamal JM; Martinez J; Osani MC; Du XL; Simpson LM; Davis BR
    JAMA Netw Open; 2023 Dec; 6(12):e2344998. PubMed ID: 38048133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST).
    Ried LD; Tueth MJ; Handberg E; Kupfer S; Pepine CJ;
    Psychosom Med; 2005; 67(3):398-406. PubMed ID: 15911902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
    Julius S; Kjeldsen SE; Weber M; Brunner HR; Ekman S; Hansson L; Hua T; Laragh J; McInnes GT; Mitchell L; Plat F; Schork A; Smith B; Zanchetti A;
    Lancet; 2004 Jun; 363(9426):2022-31. PubMed ID: 15207952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beta-blockers for hypertension.
    Wiysonge CS; Bradley H; Mayosi BM; Maroney R; Mbewu A; Opie LH; Volmink J
    Cochrane Database Syst Rev; 2007 Jan; (1):CD002003. PubMed ID: 17253471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.
    Matsuzaki M; Ogihara T; Umemoto S; Rakugi H; Matsuoka H; Shimada K; Abe K; Suzuki N; Eto T; Higaki J; Ito S; Kamiya A; Kikuchi K; Suzuki H; Tei C; Ohashi Y; Saruta T;
    J Hypertens; 2011 Aug; 29(8):1649-59. PubMed ID: 21610513
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial.
    Ogihara T; Matsuzaki M; Umemoto S; Rakugi H; Matsuoka H; Shimada K; Higaki J; Ito S; Kamiya A; Suzuki H; Ohashi Y; Shimamoto K; Saruta T;
    Hypertens Res; 2012 Apr; 35(4):441-8. PubMed ID: 22278623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Obesity paradox in patients with hypertension and coronary artery disease.
    Uretsky S; Messerli FH; Bangalore S; Champion A; Cooper-Dehoff RM; Zhou Q; Pepine CJ
    Am J Med; 2007 Oct; 120(10):863-70. PubMed ID: 17904457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. Scandinavian Study Group.
    Os I; Hotnes T; Dollerup J; Mogensen CE
    Am J Hypertens; 1997 Aug; 10(8):899-904. PubMed ID: 9270085
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age].
    Kolloch RE; Rahn KH
    Dtsch Med Wochenschr; 1998 Jan; 123(1-2):1-5. PubMed ID: 9465848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
    Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
    Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
    [TBL] [Abstract][Full Text] [Related]  

  • 51. G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
    Vandell AG; Lobmeyer MT; Gawronski BE; Langaee TY; Gong Y; Gums JG; Beitelshees AL; Turner ST; Chapman AB; Cooper-DeHoff RM; Bailey KR; Boerwinkle E; Pepine CJ; Liggett SB; Johnson JA
    Hypertension; 2012 Oct; 60(4):957-64. PubMed ID: 22949529
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
    Bangalore S; Messerli FH; Franklin SS; Mancia G; Champion A; Pepine CJ
    Eur Heart J; 2009 Jun; 30(11):1395-401. PubMed ID: 19351690
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
    Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
    Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial.
    Borhani NO; Mercuri M; Borhani PA; Buckalew VM; Canossa-Terris M; Carr AA; Kappagoda T; Rocco MV; Schnaper HW; Sowers JR; Bond MG
    JAMA; 1996 Sep; 276(10):785-91. PubMed ID: 8769587
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adult hypertension: reducing cardiovascular morbidity and mortality.
    Prescrire Int; 2005 Feb; 14(75):25-33. PubMed ID: 15751180
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Little effect of ordinary antihypertensive therapy on nocturnal high blood pressure in patients with sleep disordered breathing.
    Pelttari LH; Hietanen EK; Salo TT; Kataja MJ; Kantola IM
    Am J Hypertens; 1998 Mar; 11(3 Pt 1):272-9. PubMed ID: 9544866
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH
    Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.